Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS‐R item scores in pivotal study MCI186‐19

INTRODUCTION: Phase 3 study MCI186‐19 demonstrated less loss of physical function with edaravone versus placebo, as measured by the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS‐R) total score. A 1‐point drop in an individual ALSFRS‐R item may be clinically meaningful. We ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Brooks, Benjamin Rix, Pioro, Erik P., Katz, Jonathan, Takahashi, Fumihiro, Takei, Koji, Zhang, Jeffrey, Apple, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299623/
https://www.ncbi.nlm.nih.gov/pubmed/34816454
http://dx.doi.org/10.1002/mus.27467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299623/
https://www.ncbi.nlm.nih.gov/pubmed/34816454
http://dx.doi.org/10.1002/mus.27467

Ejemplares similares